Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
11.63
+0.50 (4.49%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Replimune Group Employees
Replimune Group had 479 employees as of March 31, 2025. The number of employees increased by 148 or 44.71% compared to the previous year.
Employees
479
Change (1Y)
148
Growth (1Y)
44.71%
Revenue / Employee
n/a
Profits / Employee
-$657,313
Market Cap
960.32M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| Kura Oncology | 260 |
| Geron | 258 |
| DBV Technologies | 161 |
| Solid Biosciences | 121 |
| Janux Therapeutics | 108 |
| Theravance Biopharma | 90 |
| Alto Neuroscience | 68 |
REPL News
- 1 day ago - JPMorgan upgrades Replimune on RP1 application resubmission - TheFly
- 1 day ago - Replimune upgraded to Overweight from Neutral at JPMorgan - TheFly
- 1 day ago - Replimune announces FDA acceptance of RP1 biologics license application - TheFly
- 1 day ago - Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma - GlobeNewsWire
- 26 days ago - Replimune Group trading resumes - TheFly
- 26 days ago - Replimune Group trading halted, volatility trading pause - TheFly
- 26 days ago - Replimune price target raised to $6 from $2 at Wedbush - TheFly
- 27 days ago - Replimune presents final first-in-human data for RP2 alone, with nivolumab - TheFly